专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

NL1036427C ACTIVATORS OF THE AUTOPHAGIC PATHWAY. 未知
公开(公告)号：NL1036427C
公开(公告)日：2010-07-26
申请号：NL1036427
申请日：2009-01-15
申请人： UNIV LEUVEN KATH , EISENBERG TOBIAS , ROCKENFELLER PATRICK , MADEO FRANK , MINOIS NADEGE , KROEMER GUIDO
发明人： EISENBERG TOBIAS , ROCKENFELLER PATRICK , MADEO FRANK , MINOIS NADEGE , KROEMER GUIDO , WINDERICKX JORIS
IPC分类号： A61K31/132 , A61P3/00 , A61P43/00

2. 发明申请

WO2010081204A3 POLYAMINE ACTIVATORS ( S PERMINE, S PERMIDINE) OF THE AUTOPHAGIC PATHWAY 审中-公开
标题翻译：自动途径的聚酰胺活化剂（S PERMINE，S PERMIDINE）
公开(公告)号：WO2010081204A3
公开(公告)日：2011-04-14
申请号：PCT/BE2010000002
申请日：2010-01-14
申请人： UNIV LEUVEN KATH , WINDERICKX JORIS , EISENBERG TOBIAS , KROEMER GUIDO , MADEO FRANK , MINOIS NADEGE , ROCKENFELLER PATRICK
发明人： WINDERICKX JORIS , EISENBERG TOBIAS , KROEMER GUIDO , MADEO FRANK , MINOIS NADEGE , ROCKENFELLER PATRICK
IPC分类号： A61K31/132 , A61P43/00
CPC分类号： A61K31/132
摘要： A polyamine compound of the group consisting of putrescine, spermine, spermidine, cholesteryl spermine, spermidine trihydrochloride, spermidine phosphate hexahydrate, spermidine phosphate hexahydrate and 1, 4 -butanediamine N- (3 -aminopropyl) -monohydrochloride or derivatives thereof or combinations thereof which are effective to activate the cellularautophagic pathway for use in a treatment to increase the survivability, lifespan or the life expectancy of an invertebrate animal/poikilotherm invertebrate animal, or to increase the average lifespan of a population of such invertebrate animals.
摘要翻译：由腐胺，精胺，亚精胺，胆固醇精胺，亚精胺三盐酸盐，亚精胺磷酸六水合物，亚磷酸六水合六水合物和1,4-丁二胺N-（3-氨丙基） - 单盐酸盐或其衍生物或其组合组成的组的多胺化合物，其为有效地激活用于治疗的细胞自噬性途径以增加无脊椎动物/无脊椎动物的生存能力，寿命或预期寿命，或增加这些无脊椎动物群体的平均寿命。

3. 发明申请

WO2010061246A1 USE OF P2X7 PATHWAY FOR ASSESSING THE SENSITIVITY OF A SUBJECT TO A CANCER TREATMENT 审中-公开
标题翻译：使用P2X7途径评估癌症治疗的敏感性
公开(公告)号：WO2010061246A1
公开(公告)日：2010-06-03
申请号：PCT/IB2008/055658
申请日：2008-11-27
申请人： INSTITUT GUSTAVE ROUSSY , INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , APETOH, Lionel , TESNIERE, Antoine , GHIRINGHELLI, François , ZITVOGEL, Laurence , KROEMER, Guido
发明人： APETOH, Lionel , TESNIERE, Antoine , GHIRINGHELLI, François , ZITVOGEL, Laurence , KROEMER, Guido
IPC分类号： C12Q1/68 , A61K38/20 , A61K31/704
CPC分类号： A61K38/1709 , A61K31/551 , A61K31/704 , A61K33/24 , A61K38/12 , A61K38/20 , A61K38/2006 , A61K38/212 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , G01N33/57407 , G01N2500/00 , G01N2800/52 , G01N2800/54 , A61K2300/00
摘要： The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inf lammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment.
摘要翻译：本发明涉及用于评估受试者对抗癌治疗的敏感性的方法，用于筛选可用于治疗癌症的化合物和用于确定受试者的转移性复发的可能性。所述方法基于发现在受试者中非功能性P2X7引发的NALP3细胞膜通路指示治疗抵抗力。本发明还涉及治疗癌症和恢复受试者对癌症治疗的敏感性的方法。

4. 发明申请

WO2008057863A1 THERAPEUTIC COMBINATION OF A PANHER/VEGFR2 KINASE INHIBITOR AND A PLATINUM COMPOUND 审中-公开
标题翻译： PANHER / VEGFR2激酶抑制剂和白蛋白化合物的治疗组合
公开(公告)号：WO2008057863A1
公开(公告)日：2008-05-15
申请号：PCT/US2007/083095
申请日：2007-10-31
申请人： BRISTOL-MYERS SQUIBB COMPANY , WONG, Tai, W. , SORIA, Jean-charles , KROEMER, Guido
发明人： WONG, Tai, W. , SORIA, Jean-charles , KROEMER, Guido
IPC分类号： A61K31/53 , A61K31/555 , A61K33/24 , A61P35/00
CPC分类号： A61K31/555 , A61K31/53 , A61K33/24 , A61K2300/00
摘要： This invention relates to a synergistic therapeutic combination of anti-cancer compounds which comprises a) a panHER/VEGFR2 kinase inhibitor, and b) a platinum compound, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. The invention also relates to treating certain cancers utilizing the combination of the invention.
摘要翻译：本发明涉及抗癌化合物的协同治疗组合，其包括a）panHER / VEGFR2激酶抑制剂，和b）铂化合物，以及任选的至少一种用于同时，分开或顺序使用的药学上可接受的载体。本发明还涉及利用本发明的组合治疗某些癌症。

5. 发明申请

WO2006006078A1 CANCER TREATMENT RESISTANCE AND AGENTS MODULATING SUCH RESISTANCE 审中-公开
标题翻译：癌症治疗电阻和剂量调节耐药性
公开(公告)号：WO2006006078A1
公开(公告)日：2006-01-19
申请号：PCT/IB2005/002629
申请日：2005-07-08
申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , INSTITUT PASTEUR , GOURDIER, Isabelle , COQUELLE, Arnaud , DUTRILLAUX, Bernard , KROEMER, Guido , PAU, Bernard
发明人： GOURDIER, Isabelle , COQUELLE, Arnaud , DUTRILLAUX, Bernard , KROEMER, Guido , PAU, Bernard
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： The present invention concerns a method for detecting in vitro resistance of cancer cells to a treatment by detecting in the cancer cells supernumerary nucleolar organizer regions (NOR), whereby identification of the presence of supernumerary NOR in the cancer cells is indicative of treatment resistance. The present invention also concerns a method for defining the capacity of a candidate agent to modulate NOR genes number of cancer cells by contacting the cancer cells with a candidate agent for a time sufficient to permit modulation of NOR genes number; and observing whether NOR genes number increases or decreases in said cancer cells. The present invention also provides a candidate agent that modulates NOR genes number of cancer cells obtained by the method of the invention and a composition for treating and/or preventing a cancer in a patient, comprising said candidate agent. Such a candidate agent decreases the NOR genes number in said cancer cells.
摘要翻译：本发明涉及一种通过在癌细胞中检测超核的核仁组织区（NOR）来检测癌细胞的体外耐药性的方法，由此鉴定癌细胞中的编号NOR的存在表示耐药性。本发明还涉及通过使癌细胞与候选试剂接触足以允许调节NOR基因数的时间来定义候选试剂调节NOR细胞数目的能力的方法; 观察所述癌细胞中NOR基因数目是否增加或减少。本发明还提供了调节通过本发明的方法获得的癌细胞的NOR基因数目的候选药剂和包含所述候选药物的患者中用于治疗和/或预防癌症的组合物。这样的候选试剂降低了所述癌细胞中的NOR基因数目。

6. 发明申请

WO2005059554A8 PUMA, PHOSPHORYLATED P53 AND P38 MAP KINASE AS MARKERS FOR HIV-1-INDUCED APOPTOSIS IN CIRCULATING T CELLS OF INFECTED PATIENT 审中-公开
标题翻译：彪马，磷酸化P53和P38 MAP激酶作为感染患者循环T细胞中HIV-1诱导的细胞凋亡的标记物
公开(公告)号：WO2005059554A8
公开(公告)日：2005-10-27
申请号：PCT/IB2004004331
申请日：2004-12-10
申请人： ROUSSY INST GUSTAVE , INST NAT SANTE RECH MED , CENTRE NAT RECH SCIENT , ISTITUTO NAZ PER LE MALATTIE I , UNIV PARIS SUD , KROEMER GUIDO , PERFETTINI JEAN-LUC , PIACENTINI MAURO
发明人： KROEMER GUIDO , PERFETTINI JEAN-LUC , PIACENTINI MAURO
IPC分类号： G01N33/569
CPC分类号： G01N33/56988 , G01N2500/00 , G01N2510/00 , G01N2800/52
摘要： The subject matter of the present invention relates to an in vitro method for the screening of anti-HIV compounds, or for predicting the progression of HIV related diseases, or for determining the efficiency of an anti-HIV-1 treatment based on the measuring of the expression level of Puma and, optionally, on the measuring of the phosphorylated p53 and/or the p38 MAP kinase protein level in circulating white blood cells of a sample from a HIV infected patient, particularly HIV-1. The invention further comprises a method for the diagnostic of HIV infection in a patient and kits for performing these methods.
摘要翻译：本发明的主题涉及用于筛选抗HIV化合物或用于预测HIV相关疾病的进展或用于基于测量抗HIV-1治疗来确定抗HIV-1治疗的效率的体外方法 Puma的表达水平以及任选地测量来自HIV感染患者，特别是HIV-1的样品的循环白血细胞中磷酸化p53和/或p38MAP激酶蛋白水平。本发明还包括用于诊断患者中HIV感染的方法和用于执行这些方法的试剂盒。

7. 发明申请

WO0182969A3 MEDICINES FOR TREATING TUMORAL PATHOLOGIES CONTAINING THE RO5-4864 COMPOUND AND AN APOPTOSIS-INDUCING AGENT 审中-公开
标题翻译：用于治疗含有RO5-4864化合物和病毒诱导剂的肿瘤病理学药物
公开(公告)号：WO0182969A3
公开(公告)日：2002-04-18
申请号：PCT/FR0101322
申请日：2001-04-27
申请人： CENTRE NAT RECH SCIENT , INST CURIE , DECAUDIN DIDIER , KROEMER GUIDO , POUPON MARIE FRANCE , NEMATI FARIBA , BEURDELEY THOMAS ARNAUD
发明人： DECAUDIN DIDIER , KROEMER GUIDO , POUPON MARIE-FRANCE , NEMATI FARIBA , BEURDELEY-THOMAS ARNAUD
IPC分类号： A61K45/00 , A61K31/5513 , A61K45/06 , A61P35/00
CPC分类号： A61K31/5513 , A61K45/06 , A61K2300/00
摘要： The invention concerns the use of Ro5-4864, and compounds derived therefrom, for preparing medicines for treating tumoral pathologies. The invention also concerns said compounds combined with an apoptosis-inducing agent, as combination products for simultaneous, separate or prolonged use, in cancer therapy.
摘要翻译：本发明涉及使用Ro5-4864及其衍生的化合物来制备治疗肿瘤病理学的药物。本发明还涉及与凋亡诱导剂组合的所述化合物，作为癌症治疗中用于同时，分别或长期使用的组合产物。

8. 发明申请

WO2012019991A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS 审中-公开
标题翻译：用于治疗HIV-1感染的方法和药物组合物
公开(公告)号：WO2012019991A1
公开(公告)日：2012-02-16
申请号：PCT/EP2011/063606
申请日：2011-08-08
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , INSTITUT PASTEUR , PERFETTINI, Jean-luc , KROEMER, Guido , GOUGEON, Marie-Lise , PIACENTINI, Mauro
发明人： PERFETTINI, Jean-luc , KROEMER, Guido , GOUGEON, Marie-Lise , PIACENTINI, Mauro
IPC分类号： C12N15/113 , A61K31/713 , A61P31/18 , A61K31/7052 , A61K38/46
CPC分类号： A61K39/42 , A61K31/7088 , A61K31/7105 , A61K31/713 , A61K38/46 , C12N15/1138 , C12N2310/14 , C12Q1/18 , C12Y306/01005 , G01N33/5041 , G01N33/56988
摘要： The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing human immunodeficiency virus type 1 (HIV-1) infection. More particularly, the present invention relates to a blocking agent of a component of the purinergic signalling pathway selected from the group consisting of pannexin 1, ATP or P2Y2 receptor for use in the treatment or prevention of HIV-1 infection.
摘要翻译：本发明提供了用于治疗或预防人类免疫缺陷病毒1型（HIV-1）感染的方法和组合物（例如药物组合物）。更具体地，本发明涉及嘌呤能信号通路成分的封闭剂，其选自用于治疗或预防HIV-1感染的潘尼辛蛋白1，ATP或P2Y2受体。

9. 发明申请

WO2012007783A1 KITS AND METHODS FOR DETECTING THE ABILITY TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT 审中-公开
标题翻译：检测受试者诱导免疫球蛋白细胞死亡的能力的检测方法
公开(公告)号：WO2012007783A1
公开(公告)日：2012-01-19
申请号：PCT/IB2010/002034
申请日：2010-07-13
申请人： INSTITUT GUSTAVE ROUSSY , ZITVOGEL, Laurence , KROEMER, Guido , DELAHAYE, Nicolas
发明人： ZITVOGEL, Laurence , KROEMER, Guido , DELAHAYE, Nicolas
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/172
摘要： The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility to a cancer treatment of a subject having a tumour. These methods comprise a step of determining the ability of the treatment, of the subject and/or of the tumour to induce an anticancer immune response, the inability of at least one of the treatment, the subject and the tumor to induce an anticancer immune response being indicative of a resistance of the subject to the therapeutic treatment of cancer. Inventors in particular identify genes specific of a human subject or of cancerous cells which can be used to predict or assess the sensitivity of a subject to a treatment of cancer. The invention also relates to particular compounds capable of activating or enhancing the immune system of a particular subject, when the subject is exposed to a therapeutic treatment of cancer or before such an exposition. It further relates to uses of such compounds, in particular to prepare a pharmaceutical composition to allow or improve the efficiency of a therapy of cancer in a subject in need thereof. The present invention in addition provides kits, methods for selecting a compound of interest, as well as pharmaceutical compositions and uses thereof.
摘要翻译：本发明涉及遗传学，免疫学和医学领域。本发明更具体地涉及用于确定具有肿瘤的受试者的癌症治疗的易感性的体外或离体方法。这些方法包括确定治疗，受试者和/或肿瘤诱导抗癌免疫应答的能力的步骤，至少一种治疗，受试者和肿瘤的不能诱导抗癌免疫应答指示受试者对癌症的治疗性治疗的抗性。发明人特别地鉴定可以用于预测或评估受试者对癌症治疗的敏感性的人受试者或癌细胞特异性的基因。本发明还涉及当受试者暴露于癌症的治疗或暴露之前能够激活或增强特定受试者的免疫系统的特定化合物。本发明还涉及这些化合物的用途，特别是制备药物组合物以允许或提高有需要的受试者的癌症治疗效率。本发明另外提供试剂盒，选择目标化合物的方法，以及药物组合物及其用途。

10. 发明申请

WO2008028968A2 COMPOUNDS REGULATING CRT, KDEL RECEPTOR AND/OR ERP-57 EXPOSURE AND USES THEREOF TO EVALUATE THE EFFICIENCY OF A CANCER TREATMENT 审中-公开
标题翻译：调节CRT，KDEL受体和/或ERP-57暴露的化合物及其用于评估癌症治疗效率的用途
公开(公告)号：WO2008028968A2
公开(公告)日：2008-03-13
申请号：PCT/EP2007/059417
申请日：2007-09-07
申请人： INSTITUT GUSTAVE ROUSSY , INSERM (Institut National de la Santé et de la Recherche Médicale) , KROEMER, Guido , ZITVOGEL, Laurence , PANARETAKIS, Theocharis
发明人： KROEMER, Guido , ZITVOGEL, Laurence , PANARETAKIS, Theocharis
IPC分类号： G01N33/50
CPC分类号： G01N33/57492 , G01N2500/10 , G01N2800/52
摘要： The present invention relates to a method for determining the susceptibility of a patient tumour cell to a cancer treatment, which method comprises the detection or measure of CRT, KDEL receptor and/or ERp57 on the surface of a tumour cell.
摘要翻译：本发明涉及一种用于确定患者肿瘤细胞对癌症治疗的易感性的方法，该方法包括检测或测量肿瘤细胞表面上的CRT，KDEL受体和/或ERp57。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式